Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRUCTURE: Daclatasvir + Peginterferon Lambda-1a in HCV GT1b
NCT01718158Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2013
- Primary completion
- Oct 2014
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of peginterferon lambda-1a and daclatasvir in hepatitis C virus infection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at 12 Weeks Post-Treatment. Started Jan 2013; status: completed.
02
Drugs
peginterferon lambda-1adaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01718158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718158.